The groundbreaking success of the copyright undeniably reshaped the medication landscape, but placing funds in companies strongly reliant on off-patent versions presents a uncertain picture. Despite early earnings were substantial, the end of patents and the rise of less expensive alternatives have weakened market share. Thus, a thorough evaluation